Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19

Since December 2019, a novel coronavirus (severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2)) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID‐19). The antiretroviral drug favipiravir (FPV) has been experimentally used for...

Descripción completa

Detalles Bibliográficos
Autores principales: Irie, Kei, Nakagawa, Atsushi, Fujita, Hirotoshi, Tamura, Ryo, Eto, Masaaki, Ikesue, Hiroaki, Muroi, Nobuyuki, Tomii, Keisuke, Hashida, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300626/
https://www.ncbi.nlm.nih.gov/pubmed/32475019
http://dx.doi.org/10.1111/cts.12827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300626/
https://www.ncbi.nlm.nih.gov/pubmed/32475019
http://dx.doi.org/10.1111/cts.12827

Ejemplares similares